Compare Abbott Laboratories (ABT) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs QUALCOMM, Inc. — how do they compare? Abbott Laboratories trades at $109.7 (market cap $187.95B), while QUALCOMM, Inc. trades at $163.26 (market cap $170.28B). The key difference: Abbott Laboratories and QUALCOMM, Inc. are close in size by market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | QCOM | |
|---|---|---|
Market Cap | $187.95B | $170.28B |
Sector | Health | Technology |
52-Week High | $136.62 | $251.10 |
52-Week Low | $82.57 | $124.07 |
Enterprise Value | $214.96B | $177.24B |
Dividend Yield | 2.32% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Qualcomm (QCOM) trades at $162.68, down 3.09% amid broader semiconductor sector pressure. The stock shows mixed signals with bearish technical indicators but strong fundamentals including recent earnings beats and a 21.01% net income margin. Recent news highlights Qualcomm's strategic pivot toward AI and data centers, though competition from Nvidia's new PC chip has sparked investor concerns. The company maintains solid cash flow generation of $14.01B from operations in 2025 and continues dividend payments.
Qualcomm presents a compelling value opportunity with a P/E of 18.53 below sector averages, supported by analyst consensus price target of $200.56 implying 23% upside. Key risks include smartphone market softness and intensifying AI competition. The company's diversification into automotive and data centers provides growth catalysts, though execution risks remain. Current levels offer attractive entry for long-term investors seeking exposure to semiconductor and AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
